First Patients Dosed in Phase 2a Proof-of-Concept Study With Rectal Formulation of TopiVert''s TOP1288 in Moderate to Severe Ulcerative Colitis
(firmenpresse) - LONDON, UNITED KINGDOM -- (Marketwired) -- 10/06/16 -- ("TopiVert" or the "Company"), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and eye, announced today that the first patients have been dosed in its Phase 2a proof-of-concept study to evaluate the safety, tolerability and efficacy of a rectal formulation of TOP1288 in symptomatic ulcerative colitis (UC) patients with moderate to severe disease activity.
TOP1288, the Company''s lead NSKI programme, is a potent inhibitor of key kinases involved in inflammation and it is being developed by TopiVert as a topical therapy for UC, a form of inflammatory bowel disease (IBD) which affects the colon. As many as 40% of patients fail to respond to current drug therapy, which is often poorly tolerated, and some patients require surgical removal of the colon in order to manage the disease.
TopiVert reported encouraging results from a Phase 1 study of a rectal formulation of TOP1288 in healthy volunteers earlier this year(1), and this has subsequently been supported by data from an additional patient cohort. These clinical data, which include encouraging biomarker responses and negligible systemic absorption, support the concept that TOP1288 has the potential to produce sustained effects in mucosal tissues after local administration, but without the undesirable side effects often seen in UC patients treated with systemically available therapies.
The ongoing Phase 2a study with TOP1288 is a randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of TOP1288 administered once daily for four weeks in symptomatic UC patients with moderate to severe disease activity. The study, which aims to recruit up to 60 patients at sites across eight European countries, is expected to report in the second half of 2017. The current study utilises a rectal formulation of TOP1288, to help demonstrate POC, and a Phase 1 study with an oral formulation of TOP1288, as the intended commercial presentation, is on track to commence in early 2017, with results also anticipated in the second half of 2017.
Please click on the following link to view the full announcement.
TopiVert Pharma Ltd
Steve Webber
Chief Scientific Officer
+44 (0)20 3763 9468
Nick Staples
Chief Business Officer
+44 (0)7818 075 816
Consilium Strategic Communications
Mary-Jane Elliott / Ivar Milligan / Hendrik Thys
+44 (0)20 3709 5700
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.10.2016 - 00:00 Uhr
Sprache: Deutsch
News-ID 1462292
Anzahl Zeichen: 2822
contact information:
Contact person:
Town:
LONDON, UNITED KINGDOM
Phone:
Kategorie:
Healthcare
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 354 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"First Patients Dosed in Phase 2a Proof-of-Concept Study With Rectal Formulation of TopiVert''s TOP1288 in Moderate to Severe Ulcerative Colitis
"
steht unter der journalistisch-redaktionellen Verantwortung von
TopiVert Pharma Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
